http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CY-1107680-T1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_45a469db8aa2254dfa1ad7f1a5cebf5c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 |
| filingDate | 2007-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a4675c024a567c7bc6fffc26b7067df |
| publicationDate | 2013-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CY-1107680-T1 |
| titleOfInvention | A THERAPEUTIC FACTOR TO ELIMINATE AN UNUSED PROTEIN POPULATION FROM PLASMA |
| abstract | Agent for the elimination of an undesired protein population from the plasma of an individual, which agent comprises a plurality of ligands bonded covalently to form a complex with a plurality of proteins in the presence of at least two or more ligands are capable of being bound to ligand binding sites present in proteins, wherein the agent is a non-protein factor other than a proline-D of formula (I-A) or (I-B) wherein R is formula (a) the group R 1 is hydrogen or halogen; X is (CH 2) N- · -CH (R 2) (CH 2) n- · -CH 2 O (CH 2) n- · CH 2 NH- · benzyl, -C ( R2) = CH-; -CH2CH (OH) -; or thiazol-2,5-diyl; Y is -SS-; - (CH2) n- · -O- · -NH- · -N (R2) - · -CH = CH- · -NHC (O) NH- · -N (R2) C (O) N (R2) - · -N [CH2C6H3 (OCH3) 2] - · -N- (CH2C6H5) - · - N (CH2C6H5) C (O) N (CH2C6H5) - · - N (alkoxyalkyl) -N (cycloalkylmethyl) - · 2,6-pyridyl · 2,5-furanyl · 2,5-thienyl · 1,2- cyclohexyl; 1,3-cyclohexyl; 1,4-cyclohexyl; 1,2-naphthyl; 1,4-naphthyl; 1,5-naphthyl; 1,6-naphthyl; biphenylene; or 1,2-phenylene, 1,3 -phenylene and 1,4-phenylene, wherein the phenylene groups are optionally substituted by 1-4 substituents, selected from halogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, -COO-lower alkyl, nitrile, 5-tetrazolyl, (2-carboxylic acid pyrrolidin-1-yl) -2-oxoethoxy, N-hydroxy, N-hydroxy oxo [1,2,4] oxadiazolyl, 2-oxo- [1,2,3,5] oxathiadiazolyl, 5-thioxo [1,2,4] oxadiazolyl and 5-tert-butylsulfanyl- [1,2,4] oxadiazolyl; X 'is - (CH2) n- · - (CH2) nCH (R2) - - (CH2) nOCH2- · -NHCH2- · benzyl · -CH = C (R2) - · -CH (OH) CH2; or thiazol-2,5-diyl; R2 is lower alkyl, lower alkoxy or benzyl and n is 0-3, or a pharmaceutically acceptable salt or mono- or dieste let it. |
| priorityDate | 2001-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.